Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AstraZeneca

Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

The Conversation

China detains five AstraZeneca staff over ‘data privacy and import breaches’

Detentions involve Chinese citizens who marketed cancer drugs for firm’s oncology division

The Guardian - UK

The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Britain could be a sci-tech superpower – if the Treasury stopped holding it back

The UK has the research base, the startups, the venture capitalists, but its presence in the global market is pitiful. The chancellor must step in

The Guardian - UK

Big Pharma Push Back On First Medicare Drug Price Cuts

Major pharmaceutical companies lashed out following a landmark deal unveiled Thursday to cut the costs of 10 key medicines, with some saying the price-setting process was not transparent.

International Business Times

Big Pharma fought to keep prices high

Big Pharma exploited patent laws to stifle competition amid Medicare price negotiations, according to a new report

Salon

Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations

Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

As Radiotherapy Redefines Cancer Care, Here's the Stock to Buy Near 52-Week Highs

A new generation of radiotherapies are redefining cancer care, offering the potential for a more powerful treatment with fewer side effects. It could become a mainstream therapy for the big "traditional" cancers that make the disease the leading cause of death worldwide, which is why Morgan Stanley forecast the radiopharma…

Barchart

Reeves should nail down UK AstraZeneca deal. A collapse would be embarrassing

Chancellor hopes to cut state aid for Speke vaccine plant to £40m. But pro-growth Treasury must not let project slip overseas

The Guardian - UK

Blow to AstraZeneca vaccine project as Reeves plans funding cuts

Chancellor reportedly seeking to cut £20m from the £65m promised by Hunt to Merseyside manufacturing plant

The Guardian - UK

The Guardian view on record payouts for CEOs: the way they live now

Editorial: The latest High Pay Centre report confirms the persistent and damaging culture of entitlement at the top of business

The Guardian - UK

Typical FTSE 100 CEO pay hits record high of £4.2 million—but U.S. peers still earn 3 times as much

AstraZeneca’s Pascal Soriot and Rolls Royce’s Tufan Erginbilgic were among the highest-paid FTSE 100 CEOs, but what they make still trails behind the average pay of S&P 500 CEOs.

Fortune

FTSE 100 chief executive pay reaches highest level on record

Bosses of UK’s biggest companies are now paid 120 times more than average full-time worker in some instances

The Guardian - UK

AstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment

AstraZeneca stock skidded Thursday despite strong quarterly sales as an FDA panel met to discuss its lung cancer treatment.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients

A renaissance is stirring in cholesterol treatment, and it could drive Merck, Novartis and other stocks higher, while delivering new choices for millions of patients.

Investors Business Daily

Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks

There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.

Investors Business Daily

Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks

These five companies may offer higher earnings and return potential with lower risk. Two Leaderboard stocks included.

Barchart

1 Biopharma Stock Setting the New Standard in Cancer Care Drugs

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer drugs significantly slowed the spread of disease in two trials, potentially establishing the medicines as the new standard of care…

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Is the British Gas boss really worth £8.2m?

The share price recovery has been partly driven by the surge in wholesale energy prices, which is beyond his control

The Independent UK

Urgent call for breast cancer drug to stop women’s lives being cut short

Women with HER2-low incurable secondary disease in Scotland currently have access, while others across the UK do not

The Guardian - UK

Will AstraZeneca be the UK’s first £200bn company?

The former pharma laggard is in a race with Shell to be the first FTSE 100 stock to be valued at £200bn

Evening Standard

FTSE 100 Live 21 May: Inflation in focus after index closes slightly down

Higher-than expected UK inflation figures disappointed the City today, with shares falling as the 2.3% Consumer Price Index reading dashed hopes of a June interest rate cut.

The Guardian - UK

AstraZeneca aims to nearly double revenues to $80bn by 2030

UK’s biggest drugmaker says it plans to launch 20 major new medicines before the end of the decade

Evening Standard

'New era of growth': AstraZeneca sets out bold plans for $80bn revenues by 2030

The growth will be fuelled by 20 new drugs that are set to launch this decade

Fortune

Tyson Fury and Mo Salah outearn Europe’s highest paid CEOs—but top U.S. execs trail only Cristiano Ronaldo's $260 million haul

Stellantis CEO Carlos Tavares had a compensation package worth $39.4 million in 2023, lower than any of the world's top 50 sports stars.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

International Monetary Fund

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.